ribociclib
novartis
[' ribo', 'breast', 'ribociclib']
asco 2023 news: supplementing endocrine therapy with ribociclib significantly decreases the relapse risk in people with hormone receptor-positive, her2-negative, early breast cancer, indicate phase 3 data.
Springer Medicine provides trustworthy, tailored, cutting-edge content for medical professionals, so they can offer their patients the best possible care.